MONTREAL and CHARLOTTE, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, to take place from September 9-11, 2024, in New York City.
The Fireside Chat will be on September 10th at 2 PM EDT. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications,
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
Chris Calabrese,
This email address is being protected from spambots. You need JavaScript enabled to view it.
Kevin Gardner,
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.53 |
| Daily Change: | -1.03 -40.23 |
| Daily Volume: | 21,114,157 |
| Market Cap: | US$81.790M |
July 11, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
